MX2023001993A - Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad. - Google Patents

Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad.

Info

Publication number
MX2023001993A
MX2023001993A MX2023001993A MX2023001993A MX2023001993A MX 2023001993 A MX2023001993 A MX 2023001993A MX 2023001993 A MX2023001993 A MX 2023001993A MX 2023001993 A MX2023001993 A MX 2023001993A MX 2023001993 A MX2023001993 A MX 2023001993A
Authority
MX
Mexico
Prior art keywords
patient
mucus
methods
lungs
treating
Prior art date
Application number
MX2023001993A
Other languages
English (en)
Inventor
Jeffrey Axelrod
Carlos Milla
Eszter Vladar
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2023001993A publication Critical patent/MX2023001993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención por lo tanto proporciona métodos para tratar una enfermedad respiratoria caracterizada por hipersecreción de mucosidad que comprende administrar a un paciente humano en necesidad de tal tratamiento un inhibidor de gama secretasa (GSI), en donde la administración de un GSI es efectiva al reducir mucosidad en pulmones de tal paciente o inhibir acumulación de mucosidad en los pulmones de dicho paciente; en algunas modalidades, los métodos de la invención son efectivos al tratar una enfermedad respiratoria seleccionada del grupo que consiste en fibrosis quística, enfermedad pulmonar obstructiva crónica, discinesia ciliar primaria, bronquitis crónica, asma, bronquiectasia idiopática y secundaria, bronquiolitis obliterante, fibrosis pulmonar idiopática y otros trastornos pulmonares fibróticos, infección respiratoria incluyendo exacerbaciones en trastornos respiratorios crónicos, y acumulación de mucosidad en respuesta a infección aguda; métodos de la invención además incluyen métodos para tratar fibrosis quística en donde un GSI se administra a un paciente a quien se le administra o en necesidad de un modulador de CFTR, en donde la mucosidad en pulmones de tal paciente se reduce o acumulación de mucosidad en pulmones de tal paciente se inhibe.
MX2023001993A 2020-08-20 2021-08-19 Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad. MX2023001993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063068235P 2020-08-20 2020-08-20
PCT/US2021/046742 WO2022040447A2 (en) 2020-08-20 2021-08-19 Methods for treating respiratory diseases characterized by mucus hypersecretion

Publications (1)

Publication Number Publication Date
MX2023001993A true MX2023001993A (es) 2023-02-27

Family

ID=80323184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001993A MX2023001993A (es) 2020-08-20 2021-08-19 Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad.

Country Status (11)

Country Link
US (1) US20230277550A1 (es)
EP (1) EP4199914A2 (es)
JP (1) JP2023538125A (es)
KR (1) KR20230052954A (es)
CN (1) CN116033895A (es)
AU (1) AU2021329507A1 (es)
BR (1) BR112023002651A2 (es)
CA (1) CA3188234A1 (es)
IL (1) IL300405A (es)
MX (1) MX2023001993A (es)
WO (1) WO2022040447A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4268824A1 (en) * 2022-04-26 2023-11-01 Manros Therapeutics Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
SE0101004D0 (sv) 2001-03-21 2001-03-21 Astrazeneca Ab New measuring technique
LT2489659T (lt) 2004-06-24 2018-03-26 Vertex Pharmaceuticals Incorporated Atp rišančios kasetės transporterių moduliatoriai
RS60205B1 (sr) 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
EP1996182A4 (en) * 2006-02-27 2009-08-12 Univ Johns Hopkins CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS
MX2008012945A (es) 2006-04-07 2009-01-15 Vertex Pharma Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp).
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8299059B2 (en) 2009-10-30 2012-10-30 Eli Lilly And Company Crystalline compound and a process for its preparation
PL3030568T3 (pl) 2013-08-08 2019-03-29 Galapagos Nv Tieno[2,3-c]pirany jako modulatory cftr
EP2932966A1 (en) 2014-04-16 2015-10-21 Novartis AG Gamma secretase inhibitors for treating respiratory diseases
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
AU2016297886B2 (en) 2015-07-24 2020-12-10 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing CFTR activity
CA3000483C (en) 2015-10-06 2024-02-13 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
US9890149B2 (en) 2015-10-07 2018-02-13 NuBridge BioSciences Isothiazole derivatives as CFTR modulators
MX2018004359A (es) 2015-10-09 2018-05-01 Abbvie Sarl Pirazolo [3,4-b] piridin-6-carboxamidas n-sulfoniladas y metodo de uso.
CA3016303A1 (en) 2016-04-26 2017-11-02 Abbvie S.A.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
SG10202106949XA (en) 2016-11-18 2021-07-29 Cystic Fibrosis Found Pyrrolopyrimidines as cftr potentiators
WO2018112149A1 (en) 2016-12-16 2018-06-21 Cystic Fibrosis Foundaton Therapeutics Inc. Bycyclic heteroaryl derivatives as cftr potentiators
CN117357638A (zh) * 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10590087B1 (en) 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof

Also Published As

Publication number Publication date
CA3188234A1 (en) 2022-02-24
IL300405A (en) 2023-04-01
CN116033895A (zh) 2023-04-28
AU2021329507A1 (en) 2023-03-09
WO2022040447A9 (en) 2022-06-16
WO2022040447A3 (en) 2022-04-28
JP2023538125A (ja) 2023-09-06
KR20230052954A (ko) 2023-04-20
US20230277550A1 (en) 2023-09-07
EP4199914A2 (en) 2023-06-28
BR112023002651A2 (pt) 2023-04-04
WO2022040447A2 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
Galeiras Vázquez et al. Respiratory management in the patient with spinal cord injury
Irwin et al. Appropriate use of antitussives and protussives: a practical review
JP2505944B2 (ja) （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
MX2023001993A (es) Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad.
Gigot et al. Treatment of hiccups
KULLY The use and abuse of nasal vasoconstrictor medications
GODMAN et al. Management of patients with tetanus: some clinical experiences with various muscle-relaxing agents
SK111894A3 (en) Pharmaceutical agents for treatment of granulomatese and fibrously pulmonary illnesess
Abdullah et al. Nasal irrigation as treatment in sinonasal symptoms relief: a review of its efficacy and clinical applications
Voelker et al. Resolution of recurrent atelectasis in spinal cord injury patients with administration of recombinant human DNase
Gipsman et al. Airway clearance in patients with neuromuscular disease
Segal Advances in inhalation therapy, with particular reference to cardiorespiratory disease
BANYAI Fifteen years' experience with carbon dioxide in the management of cough
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
Lozewicz Bladder outflow obstruction induced by ipratropium bromide
D'Alonzo et al. Salmeterol in the treatment of chronic asthma.
Prigal et al. Penicillin aerosol in the prevention and treatment of respiratory infections in allergic patients
RU2229297C2 (ru) Терапевтический агент для лечения стеноза позвоночного канала
Quibell et al. Cough and Respiratory Secretions
Ottewill et al. A Six-month Analysis of Inpatient Pulmonary Rehabilitation in Tallaght University Hospital Following COVID-19 Infection
Raman Vasomotor rhinitis-atrophic rhinitis: two ends of an autonomic spectrum
Calabrese et al. Efficacy of the Treatment of the Distal Lung in a Patient with Bronchiectasis using only Volume and Expiratory Airflow Strat-effigies: A Case Report
SU1701320A1 (ru) Способ купировани приступа бронхиальной астмы
RU2690944C1 (ru) Способ профилактики ателектаза
Salem et al. Pneumonia in Atypical Measles